Condition: Systemic Sclerosis Associated Interstitial Lung Disease · Rheumatoid Arthritis Associated Interstitial Lung Disease (RA-ILD) · Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd.
This study was conducted in a randomized, double-blind, placebo-controlled design to evaluate the efficacy and safety of Genakumab injection in the treatment of CTD-ILD including Rheumatoid Arthritis associated Interstitial Lung Disease (RA-ILD) and Systemic Sclerosis associated Interstitial Lung Disease (SSc-ILD)
This description comes directly from the study's public registry record.
shengnan wen · 15130499319 · wenshengnan@gensci-china.com
Always discuss trial participation with your own doctor first.
| Peking University Third Hospital | Beijing, Beijing Municipality, China | Recruiting |
| Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology | Wuhan, Hubei, China | Recruiting |
| Qilu Hospital of Shandong University | Jinan, Shandong, China | Recruiting |
| West China Hospital of Sichuan University | Chengdu, Sichuan, China | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06189495